Cantor Fitzgerald Reaffirms Overweight Rating for ADMA Biologics (NASDAQ:ADMA)
ADMA Biologics (NASDAQ:ADMA – Get Free Report)‘s stock had its “overweight” rating reiterated by analysts at Cantor Fitzgerald in a report released on Tuesday,Benzinga reports. They currently have a $25.00 target price on the biotechnology company’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 41.40% from the stock’s previous close. Other equities […]
ADMA Biologics (NASDAQ:ADMA – Get Free Report)‘s stock had its “overweight” rating reiterated by analysts at Cantor Fitzgerald in a report released on Tuesday,Benzinga reports. They currently have a $25.00 target price on the biotechnology company’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 41.40% from the stock’s previous close. Other equities […]
